High-throughput screening

Home > Research and development >

High-throughput screening (HTS) is essential to the drug discovery process. It consists of selecting from thousands of molecules those that could have a pharmaceutical use. To do this, large libraries of repositionable compounds are tested in a biological model with a specific therapeutic target.

With more than 15 years of expertise in the screening of relevant biological models of rare and ultra-rare diseases (immortalized cells and hIPS derivatives), the platform evaluates the feasibility, advises and guides research teams in the development of their projects, from the miniaturization of the cell assay in a microplate (96-384) to the choice of a high-throughput quantifiable biomarker.

When the cell-based assay is sufficiently robust, it performs the primary screening campaign at one or more doses in single/quadruplicates, the retests and the evaluation of the EC/IC50 on customized repositionable molecule libraries.

		AVAILABLE BIOMARKER QUANTIFICATION METHODS
HCS		Quantification of membrane proteins
		Quantification of nuclear proteins
		Proteins translocation
		Proteins colocalisation
HTS		Various biochemical tests (fluorescence; luminescence)
		Proteins quantification (Alpha Screen ; Alpha LISA ; HTFR)
		Quantification of luciferase test (Overexpression…)
		Quantification of markers in absorbance

HCS : High Content Screening

In addition to this activity, the platform carries out R&D programs allowing the development of new biochemical and molecular assays as well as new cellular tools facilitating the quantification of specific biomarkers.

Team members

Johana Tournois

Platform Manager (CECS)

Johana joined I-Stem in 2006 and has been in charge of the screening platform since 2016. She is specialized in robotics, data management and miniaturization.

Amandine Thibaudeau

Platform Engineer (CECS)

Amandine joined the platform at the end of 2022 to reinforce the Screening team. Amandine has a Master in Cellular Engineering from the University of Poitiers.

Lucas DU BREUIL

Platform Technician (CECS)

Lucas joined I-Stem and the platform in September 2023 to strengthen the high-throughput screening team. Lucas holds a BTS Biotechnologies from the Lycée du Parc des Loges in Evry-Courcouronnes.

Yanis Genevois

Apprentice Platform Technician (CECS)

Collaborations

Renata Santos

IPNP, INSERM UMRS 1622, France

ANR targetBD : Pharmacological approach to lithium-resistant bipolar disorder.

Programmes Myopharm

(AFM-Téléthon) Production of biological resources

– INSERM, Centre de Recherche en Myologie, Sorbonne Université, UMRS974, INSERM, Institut de Myologie-Faculté de Médecine de la Pitié Salpêtrière, Antoine Muchir
– CNRS UMR 5310 – INSERM U1217, Institut NeuroMyoGène, Université de Lyon, Arnaud Jacquier, Laurent Shaeffer
– INSERM U955 IMRB UPEC, Créteil, Frederic Relaix
– INSERM U1251, Marseille Medical Genetics, Valérie Delague

Publications

Identification of signaling pathways modifying human dopaminergic neuron development using a pluripotent stem cell-based high-throughput screening automated system: purinergic pathways as a proof-of-principle.

01 January 2023

Boissart Claire,

Lasbareilles Marie,

Tournois Johana,

Chatrousse Laure,

Poullion Thifaine,

Benchoua Alexandra,

Frontiers in pharmacology

Contribution of Human Pluripotent Stem Cell-Based Models to Drug Discovery for Neurological Disorders.

24 November 2021

Benchoua Alexandra,

Lasbareilles Marie,

Tournois Johana,

Cells

Rescuing compounds for Lesch-Nyhan disease identified using stem cell-based phenotypic screening.

27 February 2020

Ruillier Valentin,

Tournois Johana,

Boissart Claire,

Lasbareilles Marie,

Mahé Gurvan,

Chatrousse Laure,

Cailleret Michel,

Peschanski Marc,

Benchoua Alexandra,

JCI insight

SEE ALL THE PUBLICATIONS

Agilent

Bravo-Benchcel

Medium flow pipetting machine associated with a microplate storage station, used for the development of the first steps of the Assay development.

Agilent

Biocel 1800

The Institute’s high throughput screening platform for compound management and primary screening (2006 AFM_Inserm_Genopole)

Thermo, Biotek

Plateforme de fixation et d’immuno-marquage

Used to perform high-throughput labeling during High Content Screening (HCS) (2018 or 2019)

BMG Labtech

Clariostar

Multi-mode HTS microplate reader allowing the quantification of markers in luminescence, fluorescence, TR-FRET, Alphascreen, Alphalisa, HTRF and Absorbance. (2013 genopole)

Molecular device

CX7 Cellomics et Image Express (Lecteurs HCS)

Automated microscope for fluorescence quantification of biomarkers by immunofluorescence with objectives ranging from 5X to 63X.

Thermo Fisher Scientific

Quantstudio 12k et 7k

Real-time PCR equipment to quantify the expression of target genes in 96 or 384 wells (NGS platform)